Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer

Oligometastatic Disease Clinical Trial

— TAORMINA  

Official title:

Treatment of Oligometastatic Breast Cancer - a Randomised Phase 3 Trial Comparing Stereotactic Ablative Radiotherapy and Systemic Treatment With Systemic Treatment Alone as 1st Line Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05377047
• Other study ID #: SABO 21-01
• Status: Recruiting
• Phase: N/A
• Start date: September 19, 2022
• Est. completion date: December 31, 2027

Study information

• Verified date: April 2022
• Source: Vastra Gotaland Region
• Contact: Katarzyna Kulbacka-Ortiz, CTO
• Phone: +46721470685
• Email: katarzyna.kulbacka-ortiz[@]vgregion.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.

Description:

TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.

Patients with 1-5 metastases in 1-2 organs (confirmed by PET-CT) with any breast cancer subtype can be enrolled. All metastases must be available for SABR.

The primary aim is to investigate if the addition of SABR to the oligometastatic sites in addition to the standard first-line treatment can improve progression-free survival (PFS).

Secondary aims are to compare overall survival (OS), response rate and time to development of new lesions, acute and late toxicity. quality of life, time to start of chemotherapy (luminal patients).

Exploratory analyses:

Circulating tumour DNA as an early sign of disease progression. Immun panel for determination of the effect of SABR on patients´ immune response.

To investigate the survival for each BC subtype (Luminal, HER2+ and TNBC). To investigate survival in patients with de novo OMBC and recurrent OMBC respectively.

Stratifications are based on subtype (luminal, HER2-positive vs TNBC) and type of OMBC (de novo vs. recurrent) without formal sample size calculation for the stratification factor (exploratory analysis).

Patients with de novo metastatic OMBC that is planned for neoadjuvant treatment are recommended to complete treatment followed by standard surgery and radiotherapy or SABR towards the primary tumour lesion(s).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 345
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically or cytological confirmed recurrent OMBC.

2. Age =18 years old.

3. OMBC defined as 1-5 metastases in a maximum of two organs confirmed by PET-CT.

4. Patients already on 1st line systemic treatment can be enrolled if repeated tumour evaluations show stable disease.

5. Patients with de novo stage IV OMBC must have a controlled primary tumour regardless of primary surgery or primary systemic treatment.

6. Patients with local recurrence and OMBC must have a controlled local recurrence.

7. ECOG/WHO 0-2.

8. Life expectancy > 6 months.

9. Known ER, PgR and HER2 status of either primary tumour or metastasis (preferred).

10. If measurable lesions, each = 5 cm.

11. Symptomatic bone metastases are allowed if ablative therapy can be delivered (femoral metastasis not allowed).

12. Adequate organ function for the planned treatment according to local guide-lines.

13. For patients with liver metastasis:

• No cirrhosis or hepatitis

• Hepatic function:

• Total bilirubin level < 3.0 x institutional ULN

• ALT, AST, GGT, and alkaline phosphatase levels < 3.0 x institutional ULN

• Albumin > 2.5 mg/dL

• Metastasis not adjutant to stomach or small bowel.

14. For patients with abdominal metastases: adequate renal function with a calculated creatinine clearance of > 60mL/min.

15. Toxicities from previous adjuvant therapies (excluding alopecia) must have recovered to grade 1 (defined by CTCAE 5.0). Stable grade 2 peripheral neuropathy are considered individually by the investigator.

16. Negative pregnancy test within 14 days prior to start of treatment*.

17. If childbearing potential, willing to use an effective form of contraception*.

18. No other malignancy during the last 5 years except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix.

19. Signed informed consent and willingness to follow the trial procedures.

Exclusion Criteria:

1. > 1 line of systemic treatment for OMBC due to previous progressing disease (previous treatment of isolated local recurrences with a 2nd adjuvant treatment not included).

2. Oligometastases in brain.

3. Malignant pleural effusion or ascites.

4. Metastasis growth that involves > 3 vertebra and adjacent spinal cord, spine instability or neurological deficit resulting from compression, 25% spinal canal compromise or progressive neurological deficit.

5. Unable to undergo imaging by either CT scan or MRI.

6. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect patient compliance.

7. Pregnancy or breast-feeding.

8. Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ).

Related Conditions & MeSH terms

• Breast Cancer Stage IV
• Breast Neoplasms
• Oligometastatic Disease

Intervention

Radiation:
• SABR
Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.

Locations

Country	Name	City	State
Sweden	Sahlgrenska University Hospital	Gothenburg	Västra Götalandsregionen

Sponsors (17)

Lead Sponsor

Collaborator

Vastra Gotaland Region

Azienda Ospedaliero-Universitaria Careggi, Centrallasarettet Västerås, Gävle Hospital, Haukeland University Hospital, Karlstad Central Hospital, Karolinska University Hospital, Oslo University Hospital, Region Örebro County, Sahlgrenska University Hospital, Sweden, Skane University Hospital, St. Olavs Hospital, Sundsvall Hospital, University Hospital of North Norway, University Hospital, Umeå, University of Stavanger, Uppsala University Hospital

Country where clinical trial is conducted

Sweden, 

References & Publications (8)

David S, Tan J, Savas P, Bressel M, Kelly D, Foroudi F, Loi S, Siva S. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. Breast. 2020 Feb;49:55-62. doi: 10.1016/j.breast.2019.10.016. — View Citation

Li MP, Kelly D, Tan J, Siva S, Kron T, David S. Single-fraction stereotactic ablative body radiotherapy for sternal metastases in oligometastatic breast cancer: Technique and single institution experience. J Med Imaging Radiat Oncol. 2020 Aug;64(4):580-58 — View Citation

Milano MT, Katz AW, Zhang H, Huggins CF, Aujla KS, Okunieff P. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade. Radiother Oncol. 2019 Feb;131:45-51. doi: 10.1016/j.radonc.20 — View Citation

Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):878-86. doi: 10.1016/j.ijrobp.2011.08.036. Epub 2011 Dec 13. — View Citation

Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009 Jun;115(3):601-8. doi: 10.1007/s10549-008-0157-4. Epub 2008 Aug 22. — View Citation

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Stereotact — View Citation

Scorsetti M, Franceschini D, De Rose F, Comito T, Villa E, Iftode C, Navarria P, D'Agostino GR, Masci G, Torrisi R, Testori A, Tinterri C, Santoro A. Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. Breast. 2016 A — View Citation

Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, Alongi F, Del Conte A, Militello L, Muraro E, Martorelli D, Spazzapan S, Berretta M. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)	Time from the date of randomisation to the date of disease-progression at any site or death from any cause.	3 years after the last patient inclusion
Secondary	Overall survival (OS)	Time from the date of randomisation to the date of death from any cause.	3 years after the last patient inclusion
Secondary	Local Control Rate (LCR)	Time from the date of randomisation to the date of progress in previously treated metastases	3 years after the last patient inclusion
Secondary	Safety analysis - acute toxicity	Reported according to CTCAE v.5.0	From the first dose of SABR to 3 months after the last dose of SABR
Secondary	Safety analysis - late toxicity	Reported according to CTCAE v.5.0	From the first dose of SABR to 3 years after the last dose of SABR
Secondary	Health-related quality of life Cancer-30	European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaires Cancer-30 (EORTC-QLQ C30)	At base-line and after 3, 6, 9, 12, 18, 24 and 36 months after registration.
Secondary	Health-related quality of life Breast-23	European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Breast-23 (EORTC-QLQ B23)	At base-line and after 3, 6, 9, 12, 18, 24 and 36 months after registration.